Janux Therapeutics Inc (JANX) - Total Liabilities
Based on the latest financial reports, Janux Therapeutics Inc (JANX) has total liabilities worth $86.69 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check JANX asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Janux Therapeutics Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Janux Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Janux Therapeutics Inc balance sheet assets.
Janux Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Janux Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenzhen Cotran New Material Co Ltd Class A
SHE:300731
|
China | CN¥660.86 Million |
|
JYP Entertainment Corporation
KQ:035900
|
Korea | ₩222.12 Billion |
|
Guangdong Lvtong New Energy Electric Vehicle Technology Co. Ltd. Cl A
SHE:301322
|
China | CN¥1.09 Billion |
|
Lemon Tree Hotels Limited
NSE:LEMONTREE
|
India | Rs22.06 Billion |
|
Zhuhai Enpower Electric Co Ltd
SHE:300681
|
China | CN¥4.43 Billion |
|
Beijing Join-Cheer Software Co Ltd
SHE:002279
|
China | CN¥839.95 Million |
|
Zhongtong Bus Holding Co Ltd
SHE:000957
|
China | CN¥6.78 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Janux Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See JANX equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Janux Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Janux Therapeutics Inc (2019–2025)
The table below shows the annual total liabilities of Janux Therapeutics Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $50.70 Million | +30.89% |
| 2024-12-31 | $38.73 Million | +7.42% |
| 2023-12-31 | $36.06 Million | -16.67% |
| 2022-12-31 | $43.27 Million | +220.59% |
| 2021-12-31 | $13.50 Million | -56.26% |
| 2020-12-31 | $30.86 Million | +257.82% |
| 2019-12-31 | $8.62 Million | -- |
About Janux Therapeutics Inc
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in… Read more